Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy

Acta Cirurgica Brasileira

Volumn 24, Issue 3, 2009, Pages 189-194

  Rocha, Frederico Theobaldo Ramos ^d   Lourenço, Laercio Gomes ^a   Jucá, Mário Jorge ^b   Costa, Valéria ^c   Leal, Antenor Teixeira ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^c UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

^d NONE   (Brazil)

Author keywords

Adenocarcinoma; Chemoprevention; Cyclooxygenase inhibitors; Rats; Stomach

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COMPUTER PROGRAM; CONTROLLED STUDY; DUODENOGASTRIC REFLUX; EXPERIMENTAL SURGERY; GASTROJEJUNOSTOMY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; WISTAR RAT;

ADENOCARCINOMA; ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; DUODENOGASTRIC REFLUX; GASTRIC BYPASS; HYPERPLASIA; MALE; ODDS RATIO; PYRAZOLES; RATS; RATS, WISTAR; STOMACH; STOMACH NEOPLASMS; SULFONAMIDES;

EID: 67649763511     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502009000300005     Document Type: Article

References (26)

1. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. J Biol Chem. 1999;274(33):22903-22906
2. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Ann Rev Med. 2002;53:35-57. (Pubitemid 34177870)
3. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience. World J Gastroenterol. 2006;12(9):1336-1345
4. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000;60:5040-5044 (Pubitemid 30739757)
5. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su L-K, Sherman J, Kelloff G, Levin B, Steinbach G, the FAP Study Group. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857-860
6. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev. 2004;28:127-142 (Pubitemid 38448751)
7. Langhans P, Heger RA, Hohenstein J, Schlake W, Bünter H. Operation-sequel carcinoma of the stomach. Experimental studies of surgical techniques with or without resection. World J Surg. 1981;5:595-605. (Pubitemid 12221338)
8. 8- Kondo K, Suzuki H, Nagayo T. The influence of gastro-jejunal anastomosis on gastric carcinogenesis in rats. Gann. 1984;75:362-369 (Pubitemid 14104172)
9. Langans P, Heger RA, Stegemann B. The cancer risk in the stomach subjected to nonresecting procedures: an experimental long-term study. Scand J Gastroenterol Suppl. 1984;19:138-141 (Pubitemid 14132748)
10. Mason RC. Duodenogastric reflux in rat gastric carcinoma. Br J Surg. 1986;73(10):801-803 (Pubitemid 16007123)
11. Taylor PR, Mason RC, Filipe MI, Vaja S, Hanley DC, Murphy GM, Dowling RH, McColl I. Gastric carcinogenesis in the rat induced by duodenogastric reflux without carcinogens: morphology, mucin histochemistry, polyamine metabolism, and labelling index. Gut. 1991;32:1447-1454
12. Mello ELR, Arcuri RA, Bravo Neto GP, Simões JH. Gastric Stump cancer in rats: Role of the association between Helicobacter Pylori and entero-gastric reflux. Rev Col Bras Cir. 2003;30(6):452-459
13. Dixon MF, Path FRC, Genta R, Yardley JH, Correa P. Classification and grading of gastritis: The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161-1181
14. Ming SC, Bajtal A, Correa P, Elster K, Jarvi OH, Munoz N, Nagayo T, Stemmerman GN. Gastric dysplasia: significance and pathologic criteria. Cancer. 1984;54:1794-1801. (Pubitemid 14020607)
15. Saito T, Inokuchi K, Takayama S, Sugimura T. Sequential morphological changes in N-methyl-N′-nitro-N-nitrosoguanidine carcinogenesis in the glandular stomach of rats. J Nat Cancer Inst. 1970;44:769-783
16. Shi SR, Guo J, Cote RI, Young LL, Hawes D, Shi Y, Thu S, Taylor CR. Sensitivity and detection efficiency of a novel two step detection systen (Power Vision) for Immunohistochemistry. Appl Immunohistochem Mol Morphol 1999;7:2001-2008.
17. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxigenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9(7):1421-1426 (Pubitemid 36992325)
18. Miwa K, Hasegawa H, Fujimura T, Matsumoto H, Miyata R, Kosaka t, Miyazaki I, Hattori T. Duodenal reflux through the pylorus induces gastric adenocarcinoma in the rat. Carcinogenesis. 1992;13(12):2313-2316
19. Iseki S. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem J. 1995;27:323-328
20. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancine J, Evans J, O'Neill G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology. 1996;111:445-454 (Pubitemid 26256734)
21. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Vans rees BP, Rio MC, Haglund C, Van Lanschot JJB, Offerhaus GJA, Ristimäki A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS. 2003;111:915-925
22. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol. 2004;10(13):1971-1974 (Pubitemid 39029305)
23. Wu YL, Fu SL, Zhang YP, Qiao MM, Chen Y. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother. 2005;59(Suppl 2):289-292 (Pubitemid 43303890)
24. Cho SJ, Kim N, Kim JS, Jung HC, Song IS. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci. 2007;52:1713-1721 (Pubitemid 46870572)
25. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AHC, Sung JJY. Chemoprevention of gastric cancer by celecoxib in rats. Gut. 2004;53:195-200. (Pubitemid 38125505)
26. Yu J, Tang BD, Leung WK, To KF, Bai AHC, Zeng ZR, Ma PK, Go MYY, Hu PJ, Sung JJY. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention. World J Gastroenterol. 2005:11(1):41-45 (Pubitemid 40090133)